Evidence map›Paper›PMID 9618733›Full record

ReviewPharmacy world & science : PWS1998

Pricing and reimbursement of pharmaceuticals. A new culture for the community pharmacist.

E Moen, E L Toverud, J Grund, S Brinchmann

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmacy world & science : PWS, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Financial perspective of private pharmacies in Tehran (Iran); is it a lucrative business?Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2012
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

E MoenDepartment of Social Pharmacy, School of Pharmacy, University of Oslo, Norway.
E L Toverud
J Grund
S Brinchmann

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pricing and reimbursement of pharmaceuticals are of concern for pharmacists. Different countries have different ways of organising their health care systems. The place for pharmaceuticals within these systems also differ. This article looks into the price- and reimbursement systems for medicinal products in Germany, Sweden, the UK and Norway. Various ways of organising the pharmaceutical market emerge. Some existing measures have been in place for a long time while others have been introduced more recently. A common goal for the four countries seems to be the drive to cut costs, and attempts to do this can be directed through various reimbursement systems, by focusing on prices or by influencing the physicians' prescribing behaviour, either through the use of advice or through the use of budgets. It is important for the pharmacists to have in-depth knowledge of the price- and reimbursement system they have to work within in order to be of full service to their customers.

Indexed as

Drug CostsFees, PharmaceuticalGermanyLegislation, DrugNorwayPharmaceutical PreparationsPharmaciesReimbursement MechanismsSwedenUnited KingdomPharmaceutical Preparations

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.